Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 8/20 | 0.74 |
| ▸ | PPP5C | P53041 | 2/20 | 0.74 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.74 |
| ▸ | NPY4R | P50391 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lb-100 SCHEMBL19501013 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL2832350 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL26377801 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL13311584 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL19512780 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL12390164 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL9880148 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL9880161 | 0.84 | TFPI2 (0.74) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL12390209 | 0.84 | TFPI2 (0.74) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL14135374 | 0.83 | TFPI2 (0.77) | TFPI2PPP5CPPP2CANPY4RHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
| EP-2307344-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY INC (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2015073802-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2307344-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | Lixte Biotechnology, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010014254-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | DUSP1, PPP5C, DUSP15 | TFPI2 320/4885PPP5C 2/4885PPP2CA 31/4885 |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.